NNC0114-0006

DRUG5 trials

Sponsors

Novo Nordisk A/S

Conditions

Crohn's DiseaseDiabetesDiabetes Mellitus, Type 1InflammationRheumatoid ArthritisSystemic Lupus Erythematosus

Phase 1

Safety and Tolerability of NNC0114-0006 at Increasing Dose Levels in Subjects With Rheumatoid Arthritis

CompletedNCT01565408

Novo Nordisk A/SInflammation, Rheumatoid Arthritis

Start: 2012-03-31End: 2013-10-31Updated: 2017-02-08

An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)

TerminatedNCT01689025

Novo Nordisk A/SInflammation, Systemic Lupus Erythematosus

Start: 2012-09-30End: 2014-02-28Updated: 2014-04-08

Phase 2

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis

CompletedNCT01647451

Novo Nordisk A/SInflammation, Rheumatoid Arthritis

Start: 2012-09-30End: 2013-08-31Updated: 2017-02-07

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

CompletedNCT01751152

Novo Nordisk A/SCrohn's Disease, Inflammation

Start: 2013-02-28End: 2014-12-31Updated: 2017-03-31

A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function

CompletedNCT02443155

Novo Nordisk A/SDiabetes, Diabetes Mellitus, Type 1

Start: 2015-11-10End: 2019-02-27Updated: 2021-04-09

Related Papers

Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial.

2021-03-01130 citations

278-OR: Efficacy and Safety of Anti-interleukin (IL)-21 in Combination with Liraglutide in Adults Recently Diagnosed with Type 1 Diabetes

Diabetes2020-06-016 citations